Endometrial Cancer — FIGO

FIGO 2023 staging, with the POLEmut and p53abn molecular modifiers
Anatomical / histological sub-stage
Molecular classification (if available)
Myometrial invasion (for the p53abn rule)

About this score

When to use

Assigns the FIGO 2023 stage of endometrial cancer, which integrates histological type, lymphovascular space invasion and, where available, the molecular classification. ⁦[1]⁩

Pearls and pitfalls

Early-stage POLE-mutated disease becomes stage IAmPOLEmut, and early-stage p53-abnormal disease with myometrial invasion becomes stage IICmp53abn. ⁦[1]⁩
Summarised from the numbered sources under Evidence. Check the source before relying on a statement.
Evidence
[1] Original publication
Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Integrates histological type, lymphovascular space invasion, and — where available — molecular classification. Early-stage POLEmut disease is assigned Stage IAmPOLEmut and early-stage p53abn disease with myometrial invasion is assigned Stage IICmp53abn.
International Journal of Gynaecology and Obstetrics, 2023
Open source
Last reviewed: 2026-10
Report an error in this calculator
MedScore is an educational and clinical decision-support tool. It does not provide a diagnosis, a treatment, or a drug-dosing recommendation, and it does not replace clinical judgement or local guidelines. Confirm every result against the original source before acting on it. The treating clinician remains responsible for all decisions.
Support the developer
MedScore is free on the web and made by a medical student. If it helps you, you can support its development.
Support MedScore